PL2694544T3 - Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI) - Google Patents

Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)

Info

Publication number: PL2694544T3
Authority: PL; Poland
Prior art keywords: tfpi; monoclonal antibodies; antibodies against; tissue factor; pathway inhibitor
Prior art date: 2011-04-01

Application number

PL12762959T

Other languages

English (en)

Inventor

Zhuozhi Wang

John Murphy

Tobias Marquardt

Dieter Moosmayer

Original Assignee

Bayer Healthcare Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-01

Filing date

2012-03-30

Publication date

2019-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2694544(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-03-30 Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc

2019-07-31 Publication of PL2694544T3 publication Critical patent/PL2694544T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL12762959T 2011-04-01 2012-03-30 Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI) PL2694544T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161471101P	2011-04-01	2011-04-01
PCT/US2012/031538 WO2012135671A2 (en)	2011-04-01	2012-03-30	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP12762959.0A EP2694544B1 (en)	2011-04-01	2012-03-30	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Publications (1)

Publication Number	Publication Date
PL2694544T3 true PL2694544T3 (pl)	2019-07-31

Family

ID=46932389

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12762959T PL2694544T3 (pl)	2011-04-01	2012-03-30	Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)

Country Status (37)

Country	Link
US (5)	US20140294832A1 (pl)
EP (1)	EP2694544B1 (pl)
JP (4)	JP6170903B2 (pl)
KR (2)	KR101995302B1 (pl)
CN (2)	CN103797030B (pl)
AU (3)	AU2012236296A1 (pl)
BR (1)	BR112013025376A2 (pl)
CA (2)	CA2831907C (pl)
CL (1)	CL2013002811A1 (pl)
CO (1)	CO6890074A2 (pl)
CR (1)	CR20130499A (pl)
CU (1)	CU20130128A7 (pl)
CY (1)	CY1121538T1 (pl)
DK (1)	DK2694544T3 (pl)
DO (1)	DOP2013000218A (pl)
EA (2)	EA201991704A3 (pl)
EC (1)	ECSP13012913A (pl)
ES (1)	ES2722824T3 (pl)
GT (1)	GT201300229A (pl)
HK (1)	HK1243426A1 (pl)
HR (1)	HRP20190467T1 (pl)
HU (1)	HUE042706T2 (pl)
IL (4)	IL228633B (pl)
LT (1)	LT2694544T (pl)
MX (1)	MX2013011218A (pl)
MY (2)	MY165499A (pl)
PE (1)	PE20141149A1 (pl)
PH (4)	PH12013502039A1 (pl)
PL (1)	PL2694544T3 (pl)
PT (1)	PT2694544T (pl)
RS (1)	RS58633B1 (pl)
SG (2)	SG193594A1 (pl)
SI (1)	SI2694544T1 (pl)
TR (1)	TR201905101T4 (pl)
UA (1)	UA113623C2 (pl)
WO (1)	WO2012135671A2 (pl)
ZA (1)	ZA201308169B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101792032B1 (ko)	2008-12-19	2017-11-02	백스터 인터내셔널 인코포레이티드	Ｔｆｐｉ 억제제 및 사용 방법
US8361469B2 (en)	2008-12-22	2013-01-29	Novo Nordisk A/S	Antibodies against tissue factor pathway inhibitor
DK2542257T3 (en)	2010-03-01	2017-10-16	Bayer Healthcare Llc	OPTIMIZED MONOCLONAL ANTIBODIES AGAINST Tissue FACTOR ROAD INHIBITOR (TFPI)
KR101784030B1 (ko)	2010-03-19	2017-10-10	백스터 인터내셔널 인코포레이티드	Tfpi 저해제 및 사용 방법
CN103797030B (zh) *	2011-04-01	2017-05-31	拜尔健康护理有限责任公司	针对组织因子途径抑制物(tfpi)的单克隆抗体
KR102263685B1 (ko) *	2012-03-21	2021-06-11	다케다 야쿠힌 고교 가부시키가이샤	Tfpi 저해제 및 사용 방법
CN104185474B (zh) *	2012-03-30	2017-08-25	拜尔健康护理有限责任公司	蛋白酶调节的抗体
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
DK2970497T3 (da)	2013-03-15	2018-01-29	Bayer Healthcare Llc	Anti-tfpi-antistofvarianter med differentiel binding over et ph-interval til forbedret farmakokinetik
WO2014140240A1 (en)	2013-03-15	2014-09-18	Novo Nordisk A/S	Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
WO2015007880A1 (en) *	2013-07-19	2015-01-22	Novo Nordisk A/S	Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
WO2016042093A1 (en) *	2014-09-17	2016-03-24	Novo Nordisk A/S	Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
BR112017018328A2 (pt)	2015-02-25	2018-07-10	Mogam Institute For Biomedical Research	anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo
KR102068915B1 (ko) *	2015-08-19	2020-01-22	화이자 인코포레이티드	조직 인자 경로 억제제 항체 및 그의 용도
US20210263052A1 (en) *	2018-07-25	2021-08-26	Sony Corporation	Blood coagulation system analysis device
CN112442127A (zh) *	2019-08-29	2021-03-05	苏州康宁杰瑞生物科技有限公司	针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06153985A (ja) *	1992-11-16	1994-06-03	Teijin Ltd	モノクローナル抗体
UA112050C2 (uk) *	2008-08-04	2016-07-25	БАЄР ХЕЛСКЕР ЛЛСі	Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
US8361469B2 (en) *	2008-12-22	2013-01-29	Novo Nordisk A/S	Antibodies against tissue factor pathway inhibitor
DK2542257T3 (en) *	2010-03-01	2017-10-16	Bayer Healthcare Llc	OPTIMIZED MONOCLONAL ANTIBODIES AGAINST Tissue FACTOR ROAD INHIBITOR (TFPI)
CN103797030B (zh) *	2011-04-01	2017-05-31	拜尔健康护理有限责任公司	针对组织因子途径抑制物(tfpi)的单克隆抗体
US9592297B2 (en) *	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
US8613919B1 (en) *	2012-08-31	2013-12-24	Bayer Healthcare, Llc	High concentration antibody and protein formulations

2012
- 2012-03-30 CN CN201280026938.XA patent/CN103797030B/zh not_active Expired - Fee Related
- 2012-03-30 WO PCT/US2012/031538 patent/WO2012135671A2/en active Application Filing
- 2012-03-30 MY MYPI2013701814A patent/MY165499A/en unknown
- 2012-03-30 LT LTEP12762959.0T patent/LT2694544T/lt unknown
- 2012-03-30 PT PT12762959T patent/PT2694544T/pt unknown
- 2012-03-30 ES ES12762959T patent/ES2722824T3/es active Active
- 2012-03-30 CA CA2831907A patent/CA2831907C/en not_active Expired - Fee Related
- 2012-03-30 UA UAA201312686A patent/UA113623C2/uk unknown
- 2012-03-30 EA EA201991704A patent/EA201991704A3/ru unknown
- 2012-03-30 SG SG2013071477A patent/SG193594A1/en unknown
- 2012-03-30 EP EP12762959.0A patent/EP2694544B1/en active Active
- 2012-03-30 EA EA201301107A patent/EA034214B1/ru not_active IP Right Cessation
- 2012-03-30 PL PL12762959T patent/PL2694544T3/pl unknown
- 2012-03-30 SI SI201231558T patent/SI2694544T1/sl unknown
- 2012-03-30 AU AU2012236296A patent/AU2012236296A1/en not_active Abandoned
- 2012-03-30 RS RS20190338A patent/RS58633B1/sr unknown
- 2012-03-30 JP JP2014502846A patent/JP6170903B2/ja not_active Expired - Fee Related
- 2012-03-30 SG SG10201602606UA patent/SG10201602606UA/en unknown
- 2012-03-30 CN CN201710275470.2A patent/CN107090046A/zh active Pending
- 2012-03-30 MX MX2013011218A patent/MX2013011218A/es unknown
- 2012-03-30 KR KR1020137028821A patent/KR101995302B1/ko active IP Right Grant
- 2012-03-30 DK DK12762959.0T patent/DK2694544T3/en active
- 2012-03-30 PE PE2013002137A patent/PE20141149A1/es active IP Right Grant
- 2012-03-30 BR BR112013025376A patent/BR112013025376A2/pt active Search and Examination
- 2012-03-30 HU HUE12762959A patent/HUE042706T2/hu unknown
- 2012-03-30 TR TR2019/05101T patent/TR201905101T4/tr unknown
- 2012-03-30 MY MYPI2017001205A patent/MY190951A/en unknown
- 2012-03-30 CA CA3068997A patent/CA3068997A1/en not_active Abandoned
- 2012-03-30 US US14/009,334 patent/US20140294832A1/en not_active Abandoned
- 2012-03-30 KR KR1020197018445A patent/KR20190079698A/ko not_active Application Discontinuation
2013
- 2013-09-27 GT GT201300229A patent/GT201300229A/es unknown
- 2013-09-30 DO DO2013000218A patent/DOP2013000218A/es unknown
- 2013-09-30 PH PH12013502039A patent/PH12013502039A1/en unknown
- 2013-09-30 IL IL228633A patent/IL228633B/en active IP Right Grant
- 2013-09-30 CR CR20130499A patent/CR20130499A/es unknown
- 2013-09-30 CU CU2013000128A patent/CU20130128A7/es unknown
- 2013-09-30 CL CL2013002811A patent/CL2013002811A1/es unknown
- 2013-10-01 CO CO13233113A patent/CO6890074A2/es unknown
- 2013-10-01 EC ECSP13012913 patent/ECSP13012913A/es unknown
- 2013-10-31 ZA ZA2013/08169A patent/ZA201308169B/en unknown
2016
- 2016-07-27 US US15/221,104 patent/US20170107298A1/en not_active Abandoned
2017
- 2017-02-17 JP JP2017027825A patent/JP6363747B2/ja not_active Expired - Fee Related
- 2017-05-10 AU AU2017203105A patent/AU2017203105A1/en not_active Abandoned
2018
- 2018-01-22 US US15/877,349 patent/US20180194857A1/en not_active Abandoned
- 2018-01-25 IL IL257145A patent/IL257145A/en unknown
- 2018-02-22 HK HK18102557.1A patent/HK1243426A1/zh unknown
- 2018-06-28 JP JP2018122610A patent/JP2018172411A/ja active Pending
- 2018-12-27 US US16/234,239 patent/US20190194353A1/en not_active Abandoned
2019
- 2019-02-28 PH PH12019500441A patent/PH12019500441A1/en unknown
- 2019-02-28 PH PH12019500440A patent/PH12019500440A1/en unknown
- 2019-02-28 PH PH12019500439A patent/PH12019500439A1/en unknown
- 2019-03-08 HR HRP20190467TT patent/HRP20190467T1/hr unknown
- 2019-03-15 AU AU2019201814A patent/AU2019201814A1/en not_active Abandoned
- 2019-03-22 CY CY20191100343T patent/CY1121538T1/el unknown
2020
- 2020-05-14 IL IL274686A patent/IL274686B/en unknown
- 2020-10-20 JP JP2020176145A patent/JP2021019619A/ja not_active Withdrawn
2021
- 2021-03-24 US US17/211,631 patent/US20220041752A1/en not_active Abandoned
- 2021-06-09 IL IL283829A patent/IL283829A/en unknown

Also Published As

Publication number	Publication date
HUE042706T2 (hu)	2019-07-29
AU2012236296A1 (en)	2013-10-24
KR20140019428A (ko)	2014-02-14
UA113623C2 (uk)	2017-02-27
RS58633B1 (sr)	2019-05-31
WO2012135671A3 (en)	2012-12-13
AU2017203105A1 (en)	2017-06-01
PE20141149A1 (es)	2014-08-28
US20220041752A1 (en)	2022-02-10
IL257145A (en)	2018-03-29
CO6890074A2 (es)	2014-03-10
SI2694544T1 (sl)	2019-06-28
TR201905101T4 (tr)	2019-05-21
HRP20190467T1 (hr)	2019-05-03
EA034214B1 (ru)	2020-01-17
PH12013502039B1 (en)	2013-12-16
DOP2013000218A (es)	2013-11-15
US20170107298A1 (en)	2017-04-20
SG10201602606UA (en)	2016-04-28
LT2694544T (lt)	2019-04-25
CU20130128A7 (es)	2014-03-26
EA201991704A2 (ru)	2020-03-31
MY165499A (en)	2018-03-27
CA3068997A1 (en)	2012-10-04
ZA201308169B (en)	2016-03-30
AU2019201814A1 (en)	2019-04-04
PH12019500441A1 (en)	2020-10-12
PT2694544T (pt)	2019-04-02
CA2831907C (en)	2020-03-24
IL228633A0 (en)	2013-12-31
WO2012135671A2 (en)	2012-10-04
CY1121538T1 (el)	2020-05-29
PH12013502039A1 (en)	2013-12-16
ES2722824T3 (es)	2019-08-19
IL283829A (en)	2021-07-29
US20140294832A1 (en)	2014-10-02
EP2694544B1 (en)	2019-01-23
MY190951A (en)	2022-05-24
PH12019500440A1 (en)	2020-10-12
JP2018172411A (ja)	2018-11-08
HK1243426A1 (zh)	2018-07-13
CL2013002811A1 (es)	2014-02-28
DK2694544T3 (en)	2019-04-15
SG193594A1 (en)	2013-10-30
PH12019500439A1 (en)	2020-10-12
JP6363747B2 (ja)	2018-07-25
NZ615969A (en)	2016-01-29
ECSP13012913A (es)	2014-02-28
CN103797030A (zh)	2014-05-14
JP2017113019A (ja)	2017-06-29
CA2831907A1 (en)	2012-10-04
GT201300229A (es)	2014-11-13
US20180194857A1 (en)	2018-07-12
JP2021019619A (ja)	2021-02-18
EA201301107A1 (ru)	2014-11-28
IL274686B (en)	2021-09-30
US20190194353A1 (en)	2019-06-27
MX2013011218A (es)	2013-10-17
EP2694544A4 (en)	2015-03-25
CN103797030B (zh)	2017-05-31
BR112013025376A2 (pt)	2017-07-25
KR101995302B1 (ko)	2019-07-02
JP6170903B2 (ja)	2017-07-26
EA201991704A3 (ru)	2020-06-30
CR20130499A (es)	2013-10-24
KR20190079698A (ko)	2019-07-05
EP2694544A2 (en)	2014-02-12
CN107090046A (zh)	2017-08-25
JP2014511685A (ja)	2014-05-19
IL274686A (en)	2020-06-30
IL228633B (en)	2018-03-29

Publication	Publication Date	Title
IL283829A (en)	2021-07-29	Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
IL277391A (en)	2020-11-30	Monoclonal antibodies are effective against tissue factor pathway inhibitor (TFPI)
ZA201400768B (en)	2015-12-23	Interleukin-31 monoclonal antibody
IL220404A (en)	2017-05-29	Antiseptic antibodies
SMT201600193B (it)	2016-08-31	Nuovo anticorpo anti-dr5
ZA201206835B (en)	2013-08-28	New humanized anti-cd20 monoclonal antibory
EP2650367A4 (en)	2015-07-08	HUMAN MONOCLONAL ANTIBODY